Skip to main content

Novo Nordisk cuts some U.S. supply of Wegovy obesity drug as demand soars

Novo Nordisk said Thursday that it was cutting the supply of some doses of its popular obesity drug in the U.S. as it struggles to keep up with surging demand.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.